Global Band Ligators for Hemorrhoid Treatment Market Size By Type (Endoscopic Ligators, Non-endoscopic Ligators), By Application (Hospitals And Clinics, Ambulatory Surgical Centers), By Region, And Se...

The Global Band Ligators for Hemorrhoid Treatment Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 1.9 billion by 2031, expanding at a CAGR of 7.0% during the forecast period from 2023 to 2031. The market is experiencing robust growth driven by the rising prevalence of hemorrhoids, increased demand for minimally invasive treatments, and advancements in ligator device technology. Band ligation is a widely accepted procedure due to its cost-effectiveness, short recovery time, and high success rate in treating internal hemorrhoids, making it increasingly popular among healthcare providers and patients alike.

Drivers

Growing Incidence of Hemorrhoidal Disease:

A sedentary lifestyle, aging population, and dietary changes are contributing to the increased prevalence of hemorrhoids globally. As awareness and diagnosis rates improve, the demand for effective treatment options such as band ligation is rising.

Preference for Minimally Invasive Procedures:

Band ligation offers a less invasive alternative to surgical hemorrhoidectomy. With shorter hospital stays and minimal discomfort, patients and clinicians are shifting preference toward ligation-based solutions.

Technological Advancements in Band Ligators:

Recent innovations such as automated ligators, disposable kits, and ergonomically designed devices are enhancing procedural efficiency and outcomes, further boosting market growth.

Restraints

Lack of Awareness in Emerging Regions:

In many low- and middle-income countries, limited access to specialized gastrointestinal healthcare and lack of awareness about non-surgical hemorrhoid treatments restrain the market potential.

Potential for Post-Procedure Complications:

Though relatively safe, rubber band ligation can occasionally lead to complications like pain, bleeding, or thrombosed hemorrhoids, which may deter some clinicians or patients from opting for the procedure.

Opportunity

Expanding Geriatric Population:

The elderly population is more susceptible to hemorrhoidal conditions, providing an expanding patient base for band ligation procedures.

Rising Demand in Ambulatory Surgical Centers (ASCs):

As ASCs become more prevalent due to lower costs and shorter wait times, the demand for outpatient procedures like band ligation is expected to grow substantially.

Integration of Teleconsultation with Proctology Care:

The incorporation of telehealth consultations for initial diagnosis and follow-up is streamlining patient management and increasing procedural volumes, especially in urban healthcare systems.

Market by System Type Insights

The Single-Band Ligators segment accounted for the largest market share in 2023, largely due to their cost-effectiveness and ease of use in primary care and smaller clinics. However, Multi-Band Ligators are anticipated to grow at the fastest CAGR through 2031, driven by efficiency in treating multiple hemorrhoids in one session and reducing procedural time.

Market by End-use Insights

Hospitals dominated the market in 2023, supported by advanced infrastructure and a high patient inflow for colorectal procedures. However, Ambulatory Surgical Centers (ASCs) are expected to witness significant growth due to increased outpatient treatment preference and reduced procedural costs.

Market by Regional Insights

North America led the global band ligators market in 2023, fueled by high healthcare spending, advanced medical infrastructure, and increasing hemorrhoid incidence. Asia-Pacific is projected to register the fastest growth during the forecast period, supported by improved healthcare access, rising awareness, and a large potential patient base in countries like India and China.

Competitive Scenario

Leading companies operating in the Global Band Ligators for Hemorrhoid Treatment Market include:

Medtronic plc

Cook Medical

ConMed Corporation

Medline Industries, Inc.

OBP Medical Corporation

Banding Systems Inc.

Boston Scientific Corporation

These players are focusing on developing disposable ligator kits, expanding regional presence, and pursuing strategic partnerships with hospitals and outpatient facilities. For instance:

In 2024, Medtronic introduced a next-generation ergonomic band ligator with improved band deployment precision.

Cook Medical expanded its reach in Latin America through distribution partnerships to increase access to ligation devices.

OBP Medical launched a disposable anoscope-ligator combo kit aimed at streamlining hemorrhoid treatments in outpatient settings.

Scope of Work – Global Band Ligators for Hemorrhoid Treatment Market

Key Market Developments

2024: Medtronic launched a disposable ligation kit aimed at improving procedural safety and efficiency.

2023: ConMed introduced a portable ligator system compatible with both anoscopes and proctoscopes for diversified usage.

2025: Cook Medical announced a partnership with AI-based health platforms to improve diagnosis and referral for hemorrhoid treatments.

FAQs

1) What is the current market size of the Global Band Ligators for Hemorrhoid Treatment Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Band Ligators for Hemorrhoid Treatment Market?

The major growth driver is the increasing prevalence of hemorrhoids and the preference for minimally invasive procedures.

3) Which is the largest region during the forecast period in the Global Band Ligators for Hemorrhoid Treatment Market?

North America is expected to remain the leading region during the forecast period.

4) Which segment accounted for the largest market share in Global Band Ligators for Hemorrhoid Treatment Market?

The Single-Band Ligators segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Band Ligators for Hemorrhoid Treatment Market?

Key players include Medtronic plc, Cook Medical, ConMed Corporation, and Boston Scientific Corporation.